Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2021 Jan 19;325(3):254-264.

doi: 10.1001/jama.2020.25864.

Renato D Lopes 1 2 3 4, Ariane V S Macedo 1 5 6, Renata J Moll-Bernardes 1, Tiago M Dos Santos 3 7, Lilian Mazza 3, André Feldman 1 8, Guilherme D'Andréa Saba Arruda 1 9, Denílson C de Albuquerque 1 10, Angelina S Camiletti 1 4, Andréa S de Sousa 1 11 12, Thiago C de Paula 5, Karla G D Giusti 13, Rafael A M Domiciano 8, Márcia M Noya-Rabelo 14 15, Alan M Hamilton 14, Vitor A Loures 8, Rodrigo M Dionísio 16, Thyago A B Furquim 16, Fábio A De Luca 17, Ítalo B Dos Santos Sousa 17, Bruno S Bandeira 18, Cleverson N Zukowski 19, Ricardo G G de Oliveira 20, Noara B Ribeiro 21, Jeffer L de Moraes 22, João L F Petriz 23, Adriana M Pimentel 24, Jacqueline S Miranda 25, Bárbara E de Jesus Abufaiad 26, C Michael Gibson 27, Christopher B Granger 2, John H Alexander 2, Olga F de Souza 1 4 25; BRACE CORONA Investigators

Affiliations

Randomized Controlled Trial

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

Renato D Lopes et al. JAMA. 2021.

Abstract

Importance: It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).

Objective: To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days.

Design, setting, and participants: A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020).

Interventions: Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs.

Main outcomes and measures: The primary outcome was the number of days alive and out of the hospital through 30 days. Secondary outcomes included death, cardiovascular death, and COVID-19 progression.

Results: Among 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial. The median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline. In terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate. There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01). There also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]). The most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%).

Conclusions and relevance: Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT04364893.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lopes reported receiving grant support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Sanofi, and Pfizer; and receiving consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Sanofi, and Portola. Dr Macedo reported receiving consulting fees from Pfizer, Bayer, AstraZeneca, Novartis, Daiichi-Sankyo, Zodiac, Roche, and Janssen. Dr de Barros E Silva reported receiving grants from Pfizer, Bayer, and Roche Diagnostics; and receiving consulting fees from Pfizer, Bayer, and Roche Diagnostics. Dr Feldman reported receiving consulting fees from Pfizer, Bayer, Daiichi-Sankyo, Boehringer, and Servier. Dr D’Andrea Saba Arruda reported receiving consulting fees from Bayer, Pfizer, Servier, AstraZeneca, and Daichii Sankyo. Dr de Albuquerque reported receiving consulting fees from Boehringer Ingelheim, AstraZeneca, Bayer, and Servier. Dr de Oliveira reported receiving consulting fees from Bayer, Boehringer-Ingelheim, Servier, and Novartis. Dr Petriz reported receiving consulting fees from Bayer, Pfizer, and Daichii Sankyo. Dr Gibson reported receiving consulting fees and grants from Johnson & Johnson, Janssen, and Bayer. Dr Granger reported receiving grant support from AstraZeneca, the US Food and Drug Administration, the National Institutes of Health, GlaxoSmithKline, Medtronic, Novartis, Apple, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Janssen; receiving consulting fees from AstraZeneca, Espero, GlaxoSmithKline, Medtronic, Novartis, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Merck, Roche, Eli Lilly, and Janssen; and that all relationships with industry are listed at dcri.org/about-us/conflict-of-interest/. Dr Alexander reported receiving grant support from Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, CryoLife, CSL Behring, GlaxoSmithKline, Ferring, the US Food and Drug Administration, the National Institutes of Health, and XaTek; and receiving consulting fees from AbbVie, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, CryoLife, CSL Behring, Novo Nordisk, Pfizer, Portola, Quantum Genomics, the US Department of Veterans Affairs, XaTek, Inositec, and Zafgen. Dr de Souza reported receiving grant support from Boehringer Ingelheim; and receiving consulting fees from Pfizer, Bayer, Daiichi-Sankyo, and Boehringer Ingelheim. No other disclosures were reported.

Figures

Figure 1.

Figure 1.. Study Enrollment and Analysis in the BRACE CORONA Trial on the Use of Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

aMay have met more than 1 exclusion criterion.

Figure 2.

Figure 2.. Primary Outcome and Clinical Status at 30 Days

For the primary outcome, the mean number of days alive and out of the hospital was 21.9 days (SD, 8.0 days) in the discontinue use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) group vs 22.9 days (SD, 7.1 days) in the continue use of ACEI or ARB group (median, 25.0 days [interquartile range, 20.0-27.0 days] vs 25.0 days [interquartile range, 21.0-27.0 days], respectively) and the between-group mean ratio was 0.95 (95% CI, 0.90-1.01; P = .09).

Figure 3.

Figure 3.. Subgroup Analysis for the Primary Outcome

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CT, computed tomographic; RAAS, renin-angiotensin-aldosterone system. aThe subgroup analyses were performed using the same generalized additive model of location, scale, and shape with beta binomial distribution inflated at zero that was used for the primary outcome, including interaction terms between each subgroup and study treatments. bCalculated as weight in kilograms divided by height in meters squared. cEstimated by visual assessment performed by a radiologist. dDefined as change in clinical severity status during hospitalization. Mild defined as blood oxygen saturation of 94% or greater and lung infiltrates less than or equal to 50%; moderate, blood oxygen saturation less than 94%, or lung infiltrates greater than 50%, or ratio of partial pressure of arterial oxygen to fraction of inspired oxygen less than 300; and severe, invasive mechanical ventilation or hemodynamic instability or multiple organ dysfunction or failure.

Comment in

Similar articles

Cited by

References

    1. Gheblawi M, Wang K, Viveiros A, et al. . Angiotensin-converting enzyme 2. Circ Res. 2020;126(10):1456-1474. - PMC - PubMed
    1. Soler MJ, Barrios C, Oliva R, et al. . Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10(5):410-414. - PMC - PubMed
    1. Varagic J, Ahmad S, Nagata S, et al. . ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420. - PMC - PubMed
    1. Chung MK, Karnik S, Saef J, et al. . SARS-CoV-2 and ACE2. EBioMedicine. 2020;58:102907. - PMC - PubMed
    1. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. JAMA. 2020;323(18):1769-1770. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources